0001306830false00013068302024-08-012024-08-010001306830us-gaap:CommonStockMember2024-08-012024-08-010001306830ce:EURSeniorUnsecuredNotesDue2025Member2024-08-012024-08-010001306830ce:EURSeniorUnsecuredNotesDue2026Member2024-08-012024-08-010001306830ce:EURSeniorUnsecuredNotesDue2027Member2024-08-012024-08-010001306830ce:EURSeniorUnsecuredNotesDue2028Member2024-08-012024-08-010001306830ce:EURSeniorUnsecuredNotesDue2029Member2024-08-012024-08-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 1, 2024
CELANESE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware001-3241098-0420726
   
(State or other jurisdiction
of incorporation)		(Commission File
Number)		(IRS Employer
Identification No.)
222 West Las Colinas Blvd. Suite 900N, Irving, TX 75039
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (972) 443-4000

N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s) Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per shareCEThe New York Stock Exchange
1.250% Senior Notes due 2025CE /25The New York Stock Exchange
4.777% Senior Notes due 2026CE /26AThe New York Stock Exchange
2.125% Senior Notes due 2027CE /27The New York Stock Exchange
0.625% Senior Notes due 2028CE /28The New York Stock Exchange
5.337% Senior Notes due 2029CE /29AThe New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
1

Item 2.02 Results of Operations and Financial Condition
On August 1, 2024, Celanese Corporation (the "Company") issued a press release reporting the financial results for its second quarter 2024. A copy of the press release is attached to this Current Report on Form 8-K ("Current Report") as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 2.02 disclosure. Each Non-US GAAP financial measure appearing in the press release is accompanied by the most directly comparable US GAAP financial measure and is reconciled to the most comparable US GAAP financial measure in Exhibit 99.2, which includes other supplemental information of interest to investors, analysts and other parties, including the reasons why management believes such Non-US GAAP financial measures provide useful information to investors, and which is incorporated herein solely for purposes of this Item 2.02 disclosure.
Item 9.01 Financial Statements and Exhibits
(d) The following exhibits are being furnished herewith:
Exhibit
Number		 
Description
  
99.1
99.2
104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document contained in Exhibit 101)
* In connection with the disclosure set forth in Item 2.02, the information in this Current Report, including the exhibits attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information in this Current Report, including the exhibits, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing.
2

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    
 
CELANESE CORPORATION
 
 By:/s/ ASHLEY B. DUFFIE
 Name: Ashley B. Duffie
 Title:  Senior Vice President, General Counsel and Corporate Secretary
 
Date:
August 1, 2024
3

Exhibit 99.1
picture2a.jpg




Celanese Corporation Reports Second Quarter Earnings


Dallas, August 1, 2024: Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, today reported second quarter 2024 U.S. GAAP diluted earnings per share of $1.42 and adjusted earnings per share of $2.38. The Company generated net sales of $2.7 billion in the quarter, an increase of 2 percent from the prior quarter, reflecting a sequential increase in volume of 4 percent and sequential decrease in pricing of 2 percent.
Celanese continued to focus on execution of its controllable action plan, including driving volume growth through the project pipeline model, lowering costs through reduction of capacity in high-cost locations, and improving business efficiency through the integration of the acquired Mobility & Materials (M&M) businesses into a single SAP ERP system. These actions were especially impactful during a quarter that presented significant external headwinds. Among these headwinds were a series of outages and curtailments from multiple suppliers that led to the Company's declaration of force majeure for acetic acid and VAM sold in the Western Hemisphere, as well as persistent poor demand conditions across many of the Company's end-markets. Against the backdrop of these headwinds, the results reflect meaningful realization of business improvements from the execution of the Company's action plans. Celanese reported second quarter operating profit of $250 million, adjusted EBIT of $451 million, and operating EBITDA of $632 million at margins of 9, 17, and 24 percent, respectively.
The difference between U.S. GAAP diluted earnings per share and adjusted earnings per share in the second quarter was primarily due to Certain Items totaling $102 million.1
"In the second quarter, we delivered a double-digit sequential expansion of adjusted EBIT in spite of some of the most severe external challenges we've faced in many years," said Lori Ryerkerk, chair and chief executive officer. "The prolonged weak demand environment we have continued to experience over the past several quarters was compounded by multiple supplier failures that led us to declare force majeure for acetic acid and VAM sold in the Western Hemisphere. In this environment, we stayed focused on delivering on our action plan, which resulted in the highest ever contribution from the Engineered Materials business in our history. This highlights the importance of our execution focus, and I thank our teams for their resilience and agility to achieve these results."

1 Mainly driven by shutdown-related costs and M&A-related costs
1

Second Quarter 2024 Financial Highlights:
Three Months Ended
June 30,
2024		March 31,
2024		June 30,
2023
(unaudited)
(In $ millions, except per share data)
Net Sales
Engineered Materials1,467 1,378 1,585 
Acetyl Chain1,202 1,261 1,233 
Intersegment Eliminations(18)(28)(23)
Total2,651 2,611 2,795 
Operating Profit (Loss)
Engineered Materials138 89 158 
Acetyl Chain242 254 295 
Other Activities(130)(133)(118)
Total250 210 335 
Net Earnings (Loss)
153 124 221 
Adjusted EBIT(1)
Engineered Materials265 201 205 
Acetyl Chain277 296 332 
Other Activities(91)(90)(93)
Total451 407 444 
Equity Earnings and Dividend Income, Other Income (Expense)
Engineered Materials49 50 20 
Acetyl Chain33 36 32 
Operating EBITDA(1)
632 583 616 
Diluted EPS - continuing operations$1.42 $1.10 $2.00 
Diluted EPS - total$1.41 $1.10 $2.01 
Adjusted EPS(1)
$2.38 $2.08 $2.17 
Net cash provided by (used in) investing activities(91)(151)(163)
Net cash provided by (used in) financing activities(489)(259)(447)
Net cash provided by (used in) operating activities292 101 762 
Free cash flow(1)
173 (40)611 
____________________________
(1)See "Non-US GAAP Financial Measures" below.
2

Second Quarter Business Segment Overview
Acetyl Chain
The Acetyl Chain delivered second quarter net sales of $1.2 billion, a 5 percent decrease from the prior quarter. Volume decreased by 1 percent sequentially due to the effects of the force majeure, delayed timing of opportunistic spot sales, and muted seasonal improvements. Second quarter pricing across the Acetyl Chain decreased by 4 percent sequentially. The multiple supplier outages and curtailments had a significant impact on the ability of Celanese to produce at the Clear Lake site, the Company's lowest cost and lowest carbon footprint acetic acid unit. The second quarter total losses of Clear Lake acetic acid attributable to unplanned supplier disruptions was the highest in over 15 years. In the face of these headwinds, the Acetyl Chain worked to assure virtually all customer needs were met. The business delivered second quarter operating profit of $242 million, adjusted EBIT of $277 million, and operating EBITDA of $338 million at margins of 20, 23, and 28 percent, respectively. The Acetyl Chain has continued to exercise the unique optionality of the business model in the face of chronic low demand. The flexibility of the model allowed the business to expand volumes in downstream markets in Asia, despite poor demand conditions, by pivoting to alternate applications with available demand. The Acetyl Chain will continue to leverage this optionality to optimize outcomes through the extended demand trough.
Engineered Materials
Engineered Materials reported second quarter net sales of $1.5 billion, representing a sequential increase of 6 percent. Sequential growth was driven by a 7 percent increase in volume and stable pricing, partially offset by a small currency impact. The breadth of volume growth was widespread across the portfolio, with all 10 of the largest polymer families achieving sequential growth. This was further bolstered by a favorable mix, primarily in higher margin products and applications like Vamac® and medical implants, contributing to the overall volume increase and demonstrating the effectiveness of the project pipeline model. Engineered Materials delivered second quarter operating profit of $138 million, record adjusted EBIT of $265 million, and record operating EBITDA of $375 million. These figures represent margins of 9, 18, and 26 percent, respectively with sequential earnings improvements of 55, 32, and 24 percent. In addition to the volume growth, the sequential improvement in earnings was driven by incremental synergies and the realization of lower raw material costs. Synergy capture in the quarter included initial earnings contributions from previous initiatives such as the closure of nylon 6,6 polymerization in Uentrop, Germany. For the second consecutive quarter, these strategic actions have lifted the performance of the former M&M product portfolio to deliver the highest quarterly contribution since the acquisition.
Cash Flow and Tax
Celanese reported second quarter operating cash flow of $292 million and free cash flow of $173 million, which included cash capital expenditures of $105 million. Celanese returned $77 million in cash to shareholders via dividends in the quarter. The Company repaid a bond of approximately $500 million that matured in the second quarter as part of its deleveraging plan.


3

The effective U.S. GAAP income tax rate was an expense of 16 percent for the second quarter compared to a benefit of 2 percent for the same quarter in 2023. The effective income tax rate for the current year was higher compared to the same period in 2023, primarily due to current year tax effects related to internal debt restructuring transactions, prior year non-recurring decreases in valuation allowances on U.S. foreign tax credit carryforwards due to changes in forecasted foreign sourced income and expenses during the carryforward period, and increased earnings in high-taxed jurisdictions related to improved economic conditions in the current year. The effective tax rate for adjusted earnings was 9 percent based on expected jurisdictional earnings mix for the full year and consideration of other non-recurring U.S. GAAP items.
Outlook
"We are encouraged to see the tangible realization of our value creation initiatives in our second quarter results, and we are confident that those benefits will continue through the year," said Lori Ryerkerk. "Given the continued lack of evidence of meaningful demand recovery and the increasing pricing pressure from this low demand environment, our focus will remain on what we can control to deliver a sustainable earnings lift for Celanese. We expect the third quarter will bring an easing of the effects of the force majeure, and further improvements to our business driven by our action plans. Because of our foundational value creation initiatives, I am confident we will continue to deliver improved earnings performance in the third quarter and through the remainder of the year."
The Company anticipates third quarter adjusted earnings per share of $2.75 to $3.00. Furthermore, based on the effects of the second quarter force majeure and persistent demand challenges, the Company anticipates full year adjusted earnings per share of $10.25 to $10.75.
Reconciliations of forecasted non-GAAP measures such as adjusted earnings per share, adjusted EBIT or free cash flow to the equivalent U.S. GAAP measures (diluted earnings per share, net earnings (loss) attributable to Celanese Corporation and net cash provided by (used in) operations, respectively), are not available without unreasonable efforts because a forecast of Certain Items, such as mark-to-market pension gains/losses, and other items is not practical. For more information, see "Non-GAAP Financial Measures" below.
The Company's prepared remarks related to the second quarter will be posted on its website at investors.celanese.com under Financial Information/Financial Document Library on August 1, 2024. Information about Non-US GAAP measures is included in a Non-US GAAP Financial Measures and Supplemental Information document posted on our investor relations website under Financial Information/Non-GAAP Financial Measures. See also "Non-GAAP Financial Measures" below.
Contacts:
Investor RelationsMedia - U.S.Media - Europe
Bill CunninghamBrian BiancoPetra Czugler
Phone: +1 302 999 6410Phone: +1 972 443 4400Phone: +49 69 45009 1206
william.cunningham@celanese.commedia@celanese.competra.czugler@celanese.com
Celanese Corporation is a global leader in chemistry, producing specialty material solutions used across most major industries and consumer applications. Our businesses use our chemistry, technology and commercial expertise to create value for our customers, employees and shareholders. We support sustainability by responsibly managing the materials we create and growing our portfolio of sustainable products to meet customer and societal demand. We strive to make a positive impact in our communities and to foster inclusivity across our teams. Celanese Corporation is a Fortune 500 company that employs approximately 12,400 employees worldwide with 2023 net sales of $10.9 billion.


4

Forward-Looking Statements
This release may contain "forward-looking statements," which include information concerning the Company's plans, objectives, goals, strategies, future revenues, cash flow, financial performance, synergies, capital expenditures, financing needs and other information that is not historical information. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the Company will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the results expressed or implied in the forward-looking statements contained in this release. These risks and uncertainties include, among other things: changes in general economic, business, political and regulatory conditions in the countries or regions in which we operate; the length and depth of product and industry business cycles, particularly in the automotive, electrical, textiles, electronics and construction industries; volatility or changes in the price and availability of raw materials and energy, particularly changes in the demand for, supply of, and market prices of ethylene, methanol, natural gas, carbon monoxide, wood pulp, hexamethylene diamine and fuel oil and the prices for electricity and other energy sources; the ability to pass increases in raw materials prices, logistics costs and other costs on to customers or otherwise improve margins through price increases; the possibility that we will not be able to timely or effectively continue to integrate the Mobility & Materials business (the "M&M Business") we acquired from DuPont de Nemours, Inc. (the "M&M Acquisition") in order to realize the anticipated benefits of the M&M Acquisition, including synergies and growth opportunities, whether as a result of difficulties arising from the operation of the M&M Business or other unanticipated delays, costs, inefficiencies or liabilities; increased commercial, legal or regulatory complexity of entering into, or expanding our exposure to, certain end markets and geographies; risks in the global economy and equity and credit markets and their potential impact on our ability to pay down debt in the future and/or refinance at suitable rates, in a timely manner, or at all; risks and costs associated with increased leverage from the M&M Acquisition, including increased interest expense and potential reduction of business and strategic flexibility; the ability to maintain plant utilization rates and to implement planned capacity additions, expansions and maintenance; the ability to reduce or maintain current levels of production costs and to improve productivity by implementing technological improvements to existing plants; increased price competition and the introduction of competing products by other companies; the ability to identify desirable potential acquisition or divestiture opportunities and to complete such transactions, including obtaining regulatory approvals, consistent with the Company's strategy; market acceptance of our products and technology; compliance and other costs and potential disruption or interruption of production or operations due to accidents, interruptions in sources of raw materials, transportation, logistics or supply chain disruptions, cybersecurity incidents, terrorism or political unrest, public health crises (including, but not limited to, the COVID-19 pandemic), or other unforeseen events or delays in construction or operation of facilities, including as a result of geopolitical conditions, the direct or indirect consequences of acts of war or conflict (such as the Russia-Ukraine conflict or the Israel-Hamas conflict) or terrorist incidents or as a result of weather, natural disasters, or other crises; the ability to obtain governmental approvals and to construct facilities on terms and schedules acceptable to the Company; changes in applicable tariffs, duties and trade agreements, tax rates or legislation throughout the world including, but not limited to, anti-dumping and countervailing duties, adjustments, changes in estimates or interpretations or the resolution of tax examinations or audits that may impact recorded or future tax impacts and potential regulatory and legislative tax developments in the United States and other jurisdictions; changes in the degree of intellectual property and other legal protection afforded to our products or technologies, or the theft of such intellectual property; potential liability for remedial actions and increased costs under existing or future environmental, health and safety regulations, including those relating to climate change or other sustainability matters; potential liability resulting from pending or future claims or litigation, including investigations or enforcement actions, or from changes in the laws, regulations or policies of governments or other governmental activities in the countries in which we operate; changes in currency exchange rates and interest rates; our level of indebtedness, which could diminish our ability to raise additional capital to fund operations or limit our ability to react to changes in the economy or the chemicals industry; tax rates and changes thereto; and various other factors discussed from time to time in the Company's filings with the Securities and Exchange Commission.

Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.

Non-GAAP Financial Measures
Presentation
This document presents the Company's two business segments, Engineered Materials and the Acetyl Chain.
Use of Non-US GAAP Financial Information
This release uses the following Non-US GAAP measures: adjusted EBIT, adjusted EBIT margin, operating EBITDA, operating EBITDA margin, adjusted earnings per share and free cash flow. These measures are not recognized in accordance with US GAAP and should not be viewed as an alternative to US GAAP measures of performance or liquidity. The most directly comparable financial measure presented in accordance with US GAAP in our consolidated financial statements for adjusted EBIT and operating EBITDA is net earnings (loss) attributable to Celanese Corporation; for adjusted EBIT margin is operating margin; for operating EBITDA margin is operating margin; for adjusted earnings per share is earnings (loss) from continuing operations attributable to Celanese Corporation per common share-diluted; and for free cash flow is net cash provided by (used in) operations.
Definitions of Non-US GAAP Financial Measures
•Adjusted EBIT is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense and taxes, and further adjusted for Certain Items (refer to Table 8 of our Non-US GAAP Financial Measures and Supplemental Information document). We do not provide reconciliations for adjusted EBIT on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Adjusted EBIT margin is defined by the Company as adjusted EBIT divided by net sales.
•Operating EBITDA is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense, taxes and depreciation and amortization, and further adjusted for Certain Items, which Certain Items include accelerated depreciation and amortization expense. Operating EBITDA is equal to adjusted EBIT plus depreciation and amortization. Operating EBITDA margin is defined by the Company as operating EBITDA divided by net sales.
5

•Adjusted earnings per share is a performance measure used by the Company and is defined by the Company as earnings (loss) from continuing operations attributable to Celanese Corporation, adjusted for income tax (provision) benefit, Certain Items, and refinancing and related expenses, divided by the number of basic common shares and dilutive restricted stock units and stock options calculated using the treasury method. We do not provide reconciliations for adjusted earnings per share on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.
Note: The income tax expense (benefit) on Certain Items ("Non-GAAP adjustments") is determined using the applicable rates in the taxing jurisdictions in which the Non-GAAP adjustments occurred and includes both current and deferred income tax expense (benefit). The income tax rate used for adjusted earnings per share approximates the midpoint in a range of forecasted tax rates for the year. This range may include certain partial or full-year forecasted tax opportunities and related costs, where applicable, and specifically excludes changes in uncertain tax positions, discrete recognition of GAAP items on a quarterly basis, other pre-tax items adjusted out of our GAAP earnings for adjusted earnings per share purposes and changes in management's assessments regarding the ability to realize deferred tax assets for GAAP. In determining the adjusted earnings per share tax rate, we reflect the impact of foreign tax credits when utilized, or expected to be utilized, absent discrete events impacting the timing of foreign tax credit utilization. We analyze this rate quarterly and adjust it if there is a material change in the range of forecasted tax rates; an updated forecast would not necessarily result in a change to our tax rate used for adjusted earnings per share. The adjusted tax rate is an estimate and may differ from the actual tax rate used for GAAP reporting in any given reporting period. Table 3a of our Non-US GAAP Financial Measures and Supplemental Information document summarizes the reconciliation of our estimated GAAP effective tax rate to the adjusted tax rate. The estimated GAAP rate excludes discrete recognition of GAAP items due to our inability to forecast such items. As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate to the adjusted tax rate for actual results.
•Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operations, less capital expenditures on property, plant and equipment, and adjusted for contributions from or distributions to our noncontrolling interest joint ventures. We do not provide reconciliations for free cash flow on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of items such as working capital changes, fluctuations in foreign currency exchange rates, the impact and timing of potential acquisitions and divestitures, and other structural changes, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.
Reconciliation of Non-US GAAP Financial Measures
Reconciliations of the Non-US GAAP financial measures used in this press release to the comparable US GAAP financial measure, together with information about the purposes and uses of Non-US GAAP financial measures, are included in our Non-US GAAP Financial Measures and Supplemental Information document filed as an exhibit to our Current Report on Form 8-K filed with the SEC on or about August 1, 2024 and also available on our website at investors.celanese.com under Financial Information/Financial Document Library.
Results Unaudited
The results in this document, together with the adjustments made to present the results on a comparable basis, have not been audited and are based on internal financial data furnished to management. Quarterly results should not be taken as an indication of the results of operations to be reported for any subsequent period or for the full fiscal year.
Supplemental Information
Additional information about our prior period performance is included in our Quarterly Reports on Form 10-Q and in our Non-US GAAP Financial Measures and Supplemental Information document.
6

Consolidated Statements of Operations - Unaudited
Three Months Ended
June 30,
2024		March 31,
2024		June 30,
2023
(In $ millions, except share and per share data)
Net sales2,651 2,611 2,795 
Cost of sales(2,010)(2,057)(2,109)
Gross profit641 554 686 
Selling, general and administrative expenses(255)(265)(274)
Amortization of intangible assets(38)(41)(42)
Research and development expenses(33)(34)(40)
Other (charges) gains, net(48)(14)(10)
Foreign exchange gain (loss), net(9)11 15 
Gain (loss) on disposition of businesses and assets, net(8)(1)— 
Operating profit (loss)250 210 335 
Equity in net earnings (loss) of affiliates51 55 23 
Non-operating pension and other postretirement employee benefit (expense) income2 2 (2)
Interest expense(174)(169)(182)
Interest income10 13 7 
Dividend income - equity investments31 34 31 
Other income (expense), net13 12 4 
Earnings (loss) from continuing operations before tax183 157 216 
Income tax (provision) benefit(29)(33)4 
Earnings (loss) from continuing operations154 124 220 
Earnings (loss) from operation of discontinued operations(1)— — 
Income tax (provision) benefit from discontinued operations— — 1 
Earnings (loss) from discontinued operations(1)— 1 
Net earnings (loss)153 124 221 
Net (earnings) loss attributable to noncontrolling interests2 (3)(1)
Net earnings (loss) attributable to Celanese Corporation155 121 220 
Amounts attributable to Celanese Corporation 
Earnings (loss) from continuing operations156 121 219 
Earnings (loss) from discontinued operations(1)— 1 
Net earnings (loss)155 121 220 
Earnings (loss) per common share - basic
Continuing operations1.43 1.11 2.01 
Discontinued operations(0.01)— 0.01 
Net earnings (loss) - basic1.42 1.11 2.02 
Earnings (loss) per common share - diluted
Continuing operations1.42 1.10 2.00 
Discontinued operations(0.01)— 0.01 
Net earnings (loss) - diluted1.41 1.10 2.01 
Weighted average shares (in millions) 
Basic109.3 109.1 108.9 
Diluted109.5 109.5 109.3 
7

Consolidated Balance Sheets - Unaudited
As of
June 30,
2024		As of
December 31,
2023
(In $ millions)
ASSETS
Current Assets
Cash and cash equivalents1,185 1,805 
Trade receivables - third party and affiliates, net1,264 1,243 
Non-trade receivables, net662 541 
Inventories2,464 2,357 
Other assets329 272 
Total current assets5,904 6,218 
Investments in affiliates1,215 1,220 
Property, plant and equipment, net5,382 5,584 
Operating lease right-of-use assets381 422 
Deferred income taxes1,608 1,677 
Other assets579 524 
Goodwill6,899 6,977 
Intangible assets, net3,844 3,975 
Total assets25,812 26,597 
LIABILITIES AND EQUITY  
Current Liabilities  
Short-term borrowings and current installments of long-term debt - third party and affiliates
1,977 1,383 
Trade payables - third party and affiliates1,538 1,510 
Other liabilities1,106 1,154 
Income taxes payable5 25 
Total current liabilities4,626 4,072 
Long-term debt, net of unamortized deferred financing costs11,058 12,301 
Deferred income taxes1,039 999 
Uncertain tax positions292 300 
Benefit obligations435 457 
Operating lease liabilities282 325 
Other liabilities471 591 
Commitments and Contingencies 
Shareholders' Equity 
Treasury stock, at cost(5,487)(5,488)
Additional paid-in capital394 394 
Retained earnings13,051 12,929 
Accumulated other comprehensive income (loss), net(792)(744)
Total Celanese Corporation shareholders' equity7,166 7,091 
Noncontrolling interests443 461 
Total equity7,609 7,552 
Total liabilities and equity25,812 26,597 
8
celogo.jpg
Exhibit 99.2
Non-US GAAP Financial Measures and Supplemental Information
August 1, 2024
In this document, the terms the "Company," "we" and "our" refer to Celanese Corporation and its subsidiaries on a consolidated basis.
Purpose
The purpose of this document is to provide information of interest to investors, analysts and other parties including supplemental financial information and reconciliations and other information concerning our use of non-US GAAP financial measures. This document is updated quarterly.
Presentation
This document presents the Company's two business segments, Engineered Materials and the Acetyl Chain.
Use of Non-US GAAP Financial Measures
From time to time, management may publicly disclose certain numerical "non-GAAP financial measures" in the course of our earnings releases, financial presentations, earnings conference calls, investor and analyst meetings and otherwise. For these purposes, the Securities and Exchange Commission ("SEC") defines a "non-GAAP financial measure" as a numerical measure of historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that effectively exclude amounts, included in the most directly comparable measure calculated and presented in accordance with US GAAP, and vice versa for measures that include amounts, or are subject to adjustments that effectively include amounts, that are excluded from the most directly comparable US GAAP measure so calculated and presented. For these purposes, "GAAP" refers to generally accepted accounting principles in the United States.
Non-GAAP financial measures disclosed by management are provided as additional information to investors, analysts and other parties because the Company believes them to be important supplemental measures for assessing our financial and operating results and as a means to evaluate our financial condition and period-to-period comparisons. These non-GAAP financial measures should be viewed as supplemental to, and should not be considered in isolation or as alternatives to, net earnings (loss), operating profit (loss), operating margin, cash flow from operating activities (together with cash flow from investing and financing activities), earnings per share or any other US GAAP financial measure. These non-GAAP financial measures should be considered within the context of our complete audited and unaudited financial results for the given period, which are available on the Financial Information/Financial Document Library page of our website, investors.celanese.com. The definition and method of calculation of the non-GAAP financial measures used herein may be different from other companies' methods for calculating measures with the same or similar titles. Investors, analysts and other parties should understand how another company calculates such non-GAAP financial measures before comparing the other company's non-GAAP financial measures to any of our own. These non-GAAP financial measures may not be indicative of the historical operating results of the Company nor are they intended to be predictive or projections of future results.
Pursuant to the requirements of SEC Regulation G, whenever we refer to a non-GAAP financial measure, we will also present in this document, in the presentation itself or on a Form 8-K in connection with the presentation on the Financial Information/Financial Document Library page of our website, investors.celanese.com, to the extent practicable, the most directly comparable financial measure calculated and presented in accordance with GAAP, along with a reconciliation of the differences between the non-GAAP financial measure we reference and such comparable GAAP financial measure.
This document includes definitions and reconciliations of non-GAAP financial measures used from time to time by the Company.
Specific Measures Used
This document provides information about the following non-GAAP measures: adjusted EBIT, adjusted EBIT margin, operating EBITDA, operating EBITDA margin, operating profit (loss) attributable to Celanese Corporation, adjusted earnings per share, net debt, free cash flow and return on invested capital (adjusted). The most directly comparable financial measure presented in accordance with US GAAP in our consolidated financial statements for adjusted EBIT and operating EBITDA is net earnings (loss) attributable to Celanese Corporation; for adjusted EBIT margin and operating EBITDA margin is operating margin; for operating profit (loss) attributable to Celanese Corporation is operating profit (loss); for adjusted earnings per share is earnings (loss) from continuing operations attributable to Celanese Corporation per common share-diluted; for net debt
1
celogo.jpg
is total debt; for free cash flow is net cash provided by (used in) operations; and for return on invested capital (adjusted) is net earnings (loss) attributable to Celanese Corporation divided by the sum of the average of beginning and end of the year short- and long-term debt and Celanese Corporation shareholders' equity.
Definitions
•Adjusted EBIT is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense and taxes, and further adjusted for Certain Items (refer to Table 8). We believe that adjusted EBIT provides transparent and useful information to management, investors, analysts and other parties in evaluating and assessing our primary operating results from period-to-period after removing the impact of unusual, non-operational or restructuring-related activities that affect comparability. Our management recognizes that adjusted EBIT has inherent limitations because of the excluded items. Adjusted EBIT is one of the measures management uses for planning and budgeting, monitoring and evaluating financial and operating results and as a performance metric in the Company's incentive compensation plan. We do not provide reconciliations for adjusted EBIT on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Adjusted EBIT margin is defined by the Company as adjusted EBIT divided by net sales. Adjusted EBIT margin has the same uses and limitations as Adjusted EBIT.
•Operating EBITDA is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense, taxes and depreciation and amortization, and further adjusted for Certain Items, which Certain Items include accelerated depreciation and amortization expense. Operating EBITDA is equal to adjusted EBIT plus depreciation and amortization. We believe that Operating EBITDA provides transparent and useful information to investors, analysts and other parties in evaluating our operating performance relative to our peer companies. Operating EBITDA margin is defined by the Company as Operating EBITDA divided by net sales. Operating EBITDA margin has the same uses and limitations as Operating EBITDA.
•Operating profit (loss) attributable to Celanese Corporation is defined by the Company as operating profit (loss), less earnings (loss) attributable to noncontrolling interests ("NCI"). We believe that operating profit (loss) attributable to Celanese Corporation provides transparent and useful information to management, investors, analysts and other parties in evaluating our core operational performance. Operating margin attributable to Celanese Corporation is defined by the Company as operating profit (loss) attributable to Celanese Corporation divided by net sales. Operating margin attributable to Celanese Corporation has the same uses and limitations as Operating profit (loss) attributable to Celanese Corporation.
•Adjusted earnings per share is a performance measure used by the Company and is defined by the Company as earnings (loss) from continuing operations attributable to Celanese Corporation, adjusted for income tax (provision) benefit, Certain Items, and refinancing and related expenses, divided by the number of basic common shares and dilutive restricted stock units and stock options calculated using the treasury method. We believe that adjusted earnings per share provides transparent and useful information to management, investors, analysts and other parties in evaluating and assessing our primary operating results from period-to-period after removing the impact of the above stated items that affect comparability and as a performance metric in the Company's incentive compensation plan. We do not provide reconciliations for adjusted earnings per share on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.
Note: The income tax expense (benefit) on Certain Items ("Non-GAAP adjustments") is determined using the applicable rates in the taxing jurisdictions in which the Non-GAAP adjustments occurred and includes both current and deferred income tax expense (benefit). The income tax rate used for adjusted earnings per share approximates the midpoint in a range of forecasted tax rates for the year. This range may include certain partial or full-year forecasted tax opportunities and related costs, where applicable, and specifically excludes changes in uncertain tax positions, discrete recognition of GAAP items on a quarterly basis, other pre-tax items adjusted out of our GAAP earnings for adjusted earnings per share purposes and changes in management's assessments regarding the ability to realize deferred tax assets for GAAP. In determining the adjusted earnings per share tax rate, we reflect the impact of foreign tax credits when utilized, or expected to be utilized, absent discrete events impacting the timing of foreign tax credit utilization. We analyze this rate quarterly and adjust it if there is a material change in the range of forecasted tax rates; an updated forecast would not necessarily result in a change to our tax rate used for adjusted earnings per share. The adjusted tax rate is an estimate and may differ from the actual tax rate used for GAAP reporting in any given reporting period. Table 3a summarizes the reconciliation of our estimated GAAP effective tax rate to the adjusted tax rate. The estimated GAAP rate excludes discrete recognition of GAAP items due to our inability to forecast such items. As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate to the adjusted tax rate for actual results.
2
celogo.jpg
•Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operations, less capital expenditures on property, plant and equipment, and adjusted for contributions from or distributions to our NCI joint ventures. We believe that free cash flow provides useful information to management, investors, analysts and other parties in evaluating the Company's liquidity and credit quality assessment because it provides an indication of the long-term cash generating ability of our business. Although we use free cash flow as a measure to assess the liquidity generated by our business, the use of free cash flow has important limitations, including that free cash flow does not reflect the cash requirements necessary to service our indebtedness, lease obligations, unconditional purchase obligations or pension and postretirement funding obligations. Free cash flow is not a measure of cash available for discretionary expenditures since the Company has certain debt service and finance lease payments that are not deducted from that measure. We do not provide reconciliations for free cash flow on a forward-looking basis when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of items such as working capital changes, fluctuations in foreign currency exchange rates, the impact and timing of potential acquisitions and divestitures, and other structural changes, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.
•Net debt is defined by the Company as total debt less cash and cash equivalents. We believe that net debt provides useful information to management, investors, analysts and other parties in evaluating changes to the Company's capital structure and credit quality assessment.
•Return on invested capital (adjusted) is defined by the Company as adjusted EBIT, tax effected using the adjusted tax rate, divided by the sum of the average of beginning and end of the year short- and long-term debt and Celanese Corporation shareholders' equity. We believe that return on invested capital (adjusted) provides useful information to management, investors, analysts and other parties in order to assess our income generation from the point of view of our shareholders and creditors who provide us with capital in the form of equity and debt and whether capital invested in the Company yields competitive returns.
Supplemental Information
Supplemental Information we believe to be of interest to investors, analysts and other parties includes the following:
•Net sales for each of our business segments and the percentage increase or decrease in net sales attributable to price, volume, currency and other factors for each of our business segments.
•Cash dividends received from our equity investments.
•For those consolidated ventures in which the Company owns or is exposed to less than 100% of the economics, the outside shareholders' interests are shown as NCI. Amounts referred to as "attributable to Celanese Corporation" are net of any applicable NCI.
Results Unaudited
The results in this document, together with the adjustments made to present the results on a comparable basis, have not been audited and are based on internal financial data furnished to management. Quarterly results should not be taken as an indication of the results of operations to be reported for any subsequent period or for the full fiscal year.
3
celogo.jpg
Table 1
Celanese Adjusted EBIT and Operating EBITDA - Reconciliation of Non-GAAP Measures - Unaudited
Q2 '24Q1 '242023Q4 '23Q3 '23Q2 '23Q1 '23
(In $ millions)
Net earnings (loss) attributable to Celanese Corporation155 121 1,960 698 951 220 91 
(Earnings) loss from discontinued operations1 — 9 6 1 (1)3 
Interest income(10)(13)(39)(12)(12)(7)(8)
Interest expense174 169 720 178 178 182 182 
Refinancing expense— — 7 — 7 — — 
Income tax provision (benefit)29 33 (790)(575)(236)(4)25 
Certain Items attributable to Celanese Corporation (Table 8)
102 97 (114)139 (438)54 131 
Adjusted EBIT451 407 1,753 434 451 444 424 
Depreciation and amortization expense(1)
181 176 691 174 173 172 172 
Operating EBITDA632 583 2,444 608 624 616 596 
Q2 '24Q1 '242023Q4 '23Q3 '23Q2 '23Q1 '23
(In $ millions)
Engineered Materials11 45 15 15 — — — 
Acetyl Chain— — — — — — — 
Other Activities(2)
— — — — — — — 
Accelerated depreciation and amortization expense11 45 15 15 — — — 
Depreciation and amortization expense(1)
181 176 691 174 173 172 172 
Total depreciation and amortization expense192 221 706 189 173 172 172 
______________________________
(1)Excludes accelerated depreciation and amortization expense as detailed in the table above, which amounts are included in Certain Items above.
(2)Other Activities includes corporate Selling, general and administrative ("SG&A") expenses, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).
4
Table 2 - Supplemental Segment Data and Reconciliation of Segment Adjusted EBIT and Operating EBITDA - Non-GAAP Measures - Unaudited
celogo.jpg
Q2 '24Q1 '242023Q4 '23Q3 '23Q2 '23Q1 '23
(In $ millions, except percentages)
Operating Profit (Loss) / Operating Margin
Engineered Materials138 9.4 %89 6.5 %1,083 17.6 %122 8.7 %691 45.2 %158 10.0 %112 6.9 %
Acetyl Chain242 20.1 %254 20.1 %1,109 22.7 %264 22.4 %272 22.3 %295 23.9 %278 22.2 %
Other Activities(1)
(130)(133)(505)(127)(121)(118)(139)
Total250 9.4 %210 8.0 %1,687 15.4 %259 10.1 %842 30.9 %335 12.0 %251 8.8 %
Less: Net Earnings (Loss) Attributable to NCI for Engineered Materials(4)(1)(3)1 (2)(2)— 
Less: Net Earnings (Loss) Attributable to NCI for Acetyl Chain2 4 7 2 — 3 2 
Operating Profit (Loss) Attributable to Celanese Corporation252 9.5 %207 7.9 %1,683 15.4 %256 10.0 %844 31.0 %334 11.9 %249 8.7 %
Operating Profit (Loss) / Operating Margin Attributable to Celanese Corporation
Engineered Materials142 9.7 %90 6.5 %1,086 17.7 %121 8.6 %693 45.4 %160 10.1 %112 6.9 %
Acetyl Chain240 20.0 %250 19.8 %1,102 22.6 %262 22.2 %272 22.3 %292 23.7 %276 22.1 %
Other Activities(1)
(130)(133)(505)(127)(121)(118)(139)
Total252 9.5 %207 7.9 %1,683 15.4 %256 10.0 %844 31.0 %334 11.9 %249 8.7 %
Equity Earnings and Dividend Income, Other Income (Expense) Attributable to Celanese Corporation
Engineered Materials49 50 87 45 12 20 10 
Acetyl Chain33 36 132 33 33 32 34 
Other Activities(1)
13 15 34 28 1 6 (1)
Total95 101 253 106 46 58 43 
Non-Operating Pension and Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation
Engineered Materials— — (1)(1)— — — 
Acetyl Chain— — — — — — — 
Other Activities(1)
2 2 (68)(66)(1)(2)1 
Total2 2 (69)(67)(1)(2)1 
Certain Items Attributable to Celanese Corporation (Table 8)
Engineered Materials74 61 (324)34 (476)25 93 
Acetyl Chain4 10 24 5 5 8 6 
Other Activities(1)
24 26 186 100 33 21 32 
Total102 97 (114)139 (438)54 131 
Adjusted EBIT / Adjusted EBIT Margin
Engineered Materials265 18.1 %201 14.6 %848 13.8 %199 14.2 %229 15.0 %205 12.9 %215 13.2 %
Acetyl Chain277 23.0 %296 23.5 %1,258 25.8 %300 25.4 %310 25.4 %332 26.9 %316 25.3 %
Other Activities(1)
(91)(90)(353)(65)(88)(93)(107)
Total451 17.0 %407 15.6 %1,753 16.0 %434 16.9 %451 16.6 %444 15.9 %424 14.9 %
___________________________
(1)Other Activities includes corporate SG&A expenses, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).
5
Table 2 - Supplemental Segment Data and Reconciliation of Segment Adjusted EBIT and Operating EBITDA - Non-GAAP Measures - Unaudited (cont.)
celogo.jpg
Q2 '24Q1 '242023Q4 '23Q3 '23Q2 '23Q1 '23
(In $ millions, except percentages)
Depreciation and Amortization Expense(1)
Engineered Materials110 102 447 112 111 112 112 
Acetyl Chain61 57 217 54 55 54 54 
Other Activities(2)
10 17 27 8 7 6 6 
Total181 176 691 174 173 172 172 
Operating EBITDA / Operating EBITDA Margin
Engineered Materials375 25.6 %303 22.0 %1,295 21.1 %311 22.1 %340 22.3 %317 20.0 %327 20.1 %
Acetyl Chain338 28.1 %353 28.0 %1,475 30.2 %354 30.0 %365 29.9 %386 31.3 %370 29.6 %
Other Activities(2)
(81)(73)(326)(57)(81)(87)(101)
Total632 23.8 %583 22.3 %2,444 22.3 %608 23.7 %624 22.9 %616 22.0 %596 20.9 %
___________________________
(1)Excludes accelerated depreciation and amortization expense, which amounts are included in Certain Items above. See Table 1 for details.
(2)Other Activities includes corporate SG&A expenses, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).
6
celogo.jpg
Table 3
Adjusted Earnings (Loss) per Share - Reconciliation of a Non-GAAP Measure - Unaudited
Q2 '24Q1 '242023Q4 '23Q3 '23Q2 '23Q1 '23
per shareper shareper shareper shareper shareper shareper share
(In $ millions, except per share data)
Earnings (loss) from continuing operations attributable to Celanese Corporation156 1.42 121 1.10 1,969 18.00 704 6.43 952 8.70 219 2.00 94 0.86 
Income tax provision (benefit)29 33 (790)(575)(236)(4)25 
Earnings (loss) from continuing operations before tax185 154 1,179 129 716 215 119 
Certain Items attributable to Celanese Corporation (Table 8)
102 97 (114)139 (438)54 131 
Refinancing and related expenses— — 7 — 7 — — 
Adjusted earnings (loss) from continuing operations before tax287 251 1,072 268 285 269 250 
Income tax (provision) benefit on adjusted earnings(1)
(26)(23)(96)(23)(11)(32)(30)
Adjusted earnings (loss) from continuing operations(2)
261 2.38 228 2.08 976 8.92 245 2.24 274 2.50 237 2.17 220 2.01 
Diluted shares (in millions)(3)
Weighted average shares outstanding109.3 109.1 108.8 109.0 108.9 108.9 108.6 
Incremental shares attributable to equity awards0.2 0.4 0.6 0.5 0.5 0.4 0.6 
Total diluted shares109.5 109.5 109.4 109.5 109.4 109.3 109.2 
______________________________
(1)Calculated using adjusted effective tax rates (Table 3a) as follows:
Q2 '24Q1 '242023Q4 '23Q3 '23Q2 '23Q1 '23
Adjusted effective tax rate9 9 9 9 4 12 12 
(2)Excludes the immediate recognition of actuarial gains and losses and the impact of actual vs. expected plan asset returns.
Actual Plan Asset ReturnsExpected Plan Asset Returns
(In percentages)
20238.1 5.2 
(3)Potentially dilutive shares are included in the adjusted earnings per share calculation when adjusted earnings are positive.
7
celogo.jpg
Table 3a
Adjusted Tax Rate - Reconciliation of a Non-GAAP Measure - Unaudited
EstimatedActual
20242023
(In percentages)
US GAAP annual effective tax rate20 (67)
Discrete quarterly recognition of GAAP items(1)
(1)2 
Tax impact of other charges and adjustments(2)
(1)(3)
Changes in valuation allowances, excluding impact of other charges and adjustments(3)
(6)13 
Other, includes effect of discrete current year transactions(4)
(3)64 (5)
Adjusted tax rate9 9 
______________________________
Note: As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate for actual results.
(1)Such as changes in tax laws (including US tax reform), deferred taxes on outside basis differences, changes in uncertain tax positions and prior year audit adjustments.
(2)Reflects the tax impact on pre-tax adjustments presented in Certain Items (Table 8), which are excluded from pre-tax income for adjusted earnings per share purposes.
(3)Reflects changes in valuation allowances related to changes in judgment regarding the realizability of deferred tax assets or current year operations, excluding other charges and adjustments.
(4)Includes tax impacts related to full-year actual tax opportunities and related costs, as well as current year realization of U.S. GAAP benefits deferred in prior years.
(5)Includes the reversal of certain U.S. GAAP deferred tax benefits related to non-recurring internal restructuring transactions related to the M&M acquisition, to centralize ownership of intellectual property with the business and to facilitate future deployment of cash to service acquisition indebtedness. Certain benefits of the internal restructuring will be realized in future periods for adjusted earnings purposes.
8
celogo.jpg
Table 4
Net Sales by Segment - Unaudited
Q2 '24Q1 '242023Q4 '23Q3 '23Q2 '23Q1 '23
(In $ millions)
Engineered Materials1,467 1,378 6,149 1,406 1,528 1,585 1,630 
Acetyl Chain1,202 1,261 4,884 1,181 1,220 1,233 1,250 
Intersegment eliminations(1)
(18)(28)(93)(18)(25)(23)(27)
Net sales2,651 2,611 10,940 2,569 2,723 2,795 2,853 
___________________________
(1)Includes intersegment sales primarily related to the Acetyl Chain.
9
celogo.jpg
Table 4a
Factors Affecting Segment Net Sales Sequentially - Unaudited
Three Months Ended June 30, 2024 Compared to Three Months Ended March 31, 2024
VolumePriceCurrencyTotal
 (In percentages)
Engineered Materials7 — (1)6 
Acetyl Chain(1)(4)— (5)

Total Company4 (2)— 2 
Three Months March 31, 2024 Compared to Three Months Ended December 31, 2023
VolumePriceCurrencyTotal
(In percentages)
Engineered Materials(1)(1)— (2)
Acetyl Chain5 1 1 7 

Total Company2 — — 2 
Three Months Ended December 31, 2023 Compared to Three Months Ended September 30, 2023
VolumePriceCurrencyTotal
(In percentages)
Engineered Materials(5)(3)— (8)
(1)
Acetyl Chain— (3)— (3)

Total Company(3)(3)— (6)
Three Months Ended September 30, 2023 Compared to Three Months Ended June 30, 2023
VolumePriceCurrencyTotal
(In percentages)
Engineered Materials(1)(3)— (4)
Acetyl Chain3 (3)(1)(1)

Total Company1 (3)(1)(3)
________________________
(1)Includes the effect of the formation of the Nutrinova joint venture.


Three Months Ended June 30, 2023 Compared to Three Months Ended March 31, 2023
VolumePriceCurrencyTotal
(In percentages)
Engineered Materials2 (5)— (3)
Acetyl Chain2 (3)— (1)

Total Company2 (4)— (2)
Three Months Ended March 31, 2023 Compared to Three Months Ended December 31, 2022
VolumePriceCurrencyTotal
(In percentages)
Engineered Materials34 (4)2 32 
Acetyl Chain10 (2)2 10 

Total Company19 (4)2 17 
10
celogo.jpg
Table 4b
Factors Affecting Segment Net Sales Year Over Year - Unaudited
Three Months Ended June 30, 2024 Compared to Three Months Ended June 30, 2023
VolumePriceCurrencyTotal
 (In percentages)
Engineered Materials(2)(4)(1)(7)
Acetyl Chain4 (6)(1)(3)
Total Company1 (5)(1)(5)
Three Months Ended March 31, 2024 Compared to Three Months Ended March 31, 2023
VolumePriceCurrencyTotal
(In percentages)
Engineered Materials(12)(2)(1)(15)
Acetyl Chain11 (10)— 1 
Total Company(2)(5)(1)(8)
Three Months Ended December 31, 2023 Compared to Three Months Ended December 31, 2022
VolumePriceCurrencyTotal
(In percentages)
Engineered Materials21 (8)1 14 
Acetyl Chain14 (11)1 4 
Total Company18 (10)1 9 
Three Months Ended September 30, 2023 Compared to Three Months Ended September 30, 2022
VolumePriceCurrencyTotal
(In percentages)
Engineered Materials75 (12)1 64 
Acetyl Chain4 (18)1 (13)
Total Company33 (16)1 18 


Three Months Ended June 30, 2023 Compared to Three Months Ended June 30, 2022
VolumePriceCurrencyTotal
 (In percentages)
Engineered Materials75 (8)— 67 
Acetyl Chain(2)(19)— (21)
Total Company27 (15)— 12 
Three Months Ended March 31, 2023 Compared to Three Months Ended March 31, 2022
VolumePriceCurrencyTotal
 (In percentages)
Engineered Materials80 2 (3)79 
Acetyl Chain(9)(13)(2)(24)
Total Company23 (8)(3)12 
11
celogo.jpg
Table 4c
Factors Affecting Segment Net Sales Year Over Year - Unaudited
Year Ended December 31, 2023 Compared to Year Ended December 31, 2022
VolumePriceCurrencyTotal
 (In percentages)
Engineered Materials54 (1)— 53 
Acetyl Chain2 (17)— (15)
Total Company23 (10)— 13 

12
celogo.jpg
Table 5
Free Cash Flow - Reconciliation of a Non-GAAP Measure - Unaudited
Q2 '24Q1 '242023Q4 '23Q3 '23Q2 '23Q1 '23
(In $ millions, except percentages)
Net cash provided by (used in) investing activities(91)(151)(134)(168)375 (163)(178)
Net cash provided by (used in) financing activities(489)(259)(1,456)(240)(700)(447)(69)
Net cash provided by (used in) operating activities292 101 1,899 830 403 762 (96)
Capital expenditures on property, plant and equipment(105)(137)(568)(128)(131)(145)(164)
Contributions from/(Distributions) to NCI(14)(4)(11)— (4)(6)(1)
Free cash flow(1)
173 (40)1,320 702 268 611 (261)
Net sales2,651 2,611 10,940 2,569 2,723 2,795 2,853 
Free cash flow as % of Net sales6.5 %(1.5)%12.1 %27.3 %9.8 %21.9 %(9.1)%
______________________________
(1)Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operating activities, less capital expenditures on property, plant and equipment, and adjusted for contributions from or distributions to our NCI joint ventures.
13
celogo.jpg
Table 6
Cash Dividends Received - Unaudited
Q2 '24Q1 '242023Q4 '23Q3 '23Q2 '23Q1 '23
(In $ millions)
Dividends from equity method investments69 27 157 85 7 25 40 
Dividends from equity investments without readily determinable fair values31 34 126 31 30 31 34 
Total100 61 283 116 37 56 74 
Table 7
Net Debt - Reconciliation of a Non-GAAP Measure - Unaudited
Q2 '24Q1 '242023Q4 '23Q3 '23Q2 '23Q1 '23
(In $ millions)
Short-term borrowings and current installments of long-term debt - third party and affiliates1,977 2,439 1,383 1,383 1,408 1,507 1,386 
Long-term debt, net of unamortized deferred financing costs11,058 11,018 12,301 12,301 12,291 12,889 13,396 
Total debt13,035 13,457 13,684 13,684 13,699 14,396 14,782 
Cash and cash equivalents(1,185)(1,483)(1,805)(1,805)(1,357)(1,296)(1,167)
Net debt11,850 11,974 11,879 11,879 12,342 13,100 13,615 
14
celogo.jpg
Table 8
Certain Items - Unaudited
The following Certain Items attributable to Celanese Corporation are included in Net earnings (loss) and are adjustments to non-GAAP measures:
Q2 '24Q1 '242023Q4 '23Q3 '23Q2 '23Q1 '23Income Statement Classification
(In $ millions)
Exit and shutdown costs69 68 89 33 9 21 26 Cost of sales / SG&A / Other (charges) gains, net / Gain (loss) on disposition of businesses and assets, net / Non-operating pension and other postretirement employee benefit (expense) income
Asset impairments3 — 15 6 9 — — Cost of sales / Other (charges) gains, net
Impact from plant incidents and natural disasters(1)
— 7 6 — — — 6 Cost of sales
Mergers, acquisitions and dispositions26 25 195 27 46 23 99 Cost of sales / SG&A
Actuarial (gain) loss on pension and postretirement plans— — 69 69 — — — Cost of sales / SG&A / Non-operating pension and other postretirement employee benefit (expense) income
Legal settlements and commercial disputes3 (8)12 4 2 6 — Cost of sales / SG&A / Other (charges) gains, net
(Gain) loss on disposition of businesses and assets1 — (510)(3)(508)1 — Gain (loss) on disposition of businesses and assets, net
Other— 5 10 3 4 3 — Cost of sales / SG&A
Certain Items attributable to Celanese Corporation102 97 (114)139 (438)54 131 
___________________________
(1)Primarily associated with Winter Storms Heather and Elliott in 2024 and 2023, respectively.
15
celogo.jpg
Table 9
Return on Invested Capital (Adjusted) - Presentation of a Non-GAAP Measure - Unaudited
2023
(In $ millions, except percentages)
Net earnings (loss) attributable to Celanese Corporation1,960 
Adjusted EBIT (Table 1)
1,753 
Adjusted effective tax rate (Table 3a)
9 %
Adjusted EBIT tax effected1,595 
20232022Average
(In $ millions, except percentages)
Short-term borrowings and current installments of long-term debt - third parties and affiliates1,383 1,306 1,345 
Long-term debt, net of unamortized deferred financing costs12,301 13,373 12,837 
Celanese Corporation shareholders' equity7,091 5,637 6,364 
Invested capital20,546 
Return on invested capital (adjusted)7.8 %
Net earnings (loss) attributable to Celanese Corporation as a percentage of invested capital9.5 %
16
v3.24.2.u1
Cover Page
Aug. 01, 2024
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Aug. 01, 2024
Entity Registrant Name CELANESE CORPORATION
Entity Incorporation, State or Country Code DE
Entity File Number 001-32410
Entity Tax Identification Number 98-0420726
Entity Address, Address Line One 222 West Las Colinas Blvd. Suite 900N
Entity Address, City or Town Irving
Entity Address, State or Province TX
Entity Address, Postal Zip Code 75039
City Area Code 972
Local Phone Number 443-4000
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001306830
Amendment Flag false
Common Stock, par value $0.0001 per share  
Entity Information [Line Items]  
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol CE
Security Exchange Name NYSE
1.250% Senior Notes due 2025  
Entity Information [Line Items]  
Title of 12(b) Security 1.250% Senior Notes due 2025
Trading Symbol CE /25
Security Exchange Name NYSE
4.777% Senior Notes due 2026  
Entity Information [Line Items]  
Title of 12(b) Security 4.777% Senior Notes due 2026
Trading Symbol CE /26A
Security Exchange Name NYSE
2.125% Senior Notes due 2027  
Entity Information [Line Items]  
Title of 12(b) Security 2.125% Senior Notes due 2027
Trading Symbol CE /27
Security Exchange Name NYSE
0.625% Senior Notes due 2028  
Entity Information [Line Items]  
Title of 12(b) Security 0.625% Senior Notes due 2028
Trading Symbol CE /28
Security Exchange Name NYSE
5.337% Senior Notes due 2029  
Entity Information [Line Items]  
Title of 12(b) Security 5.337% Senior Notes due 2029
Trading Symbol CE /29A
Security Exchange Name NYSE
Celanese (NYSE:CE)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024 Plus de graphiques de la Bourse Celanese
Celanese (NYSE:CE)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024 Plus de graphiques de la Bourse Celanese